Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection

Next Previous
Trial Profile

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remdesivir (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Expanded access
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 05 Oct 2020 Status changed from recruiting to completed.
    • 29 Apr 2020 According to a Froedtert & the Medical College of Wisconsin media release, Mary Beth Graham, MD, associate chief of the division of Infectious Disease at Medical College of Wisconsin, medical director of Infection Prevention & Control at Froedtert Hospital will be the principal investigator of the study.
    • 29 Apr 2020 According to a Froedtert & the Medical College of Wisconsin media release, the institute has recently granted an approval for the enrollment into Gilead Sciences expanded access program (EAP) to treat COVID-19 patients.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top